Geriatric Medicine Doctors in El Paso, TX Accepting Medicare

6 Geriatric Medicine doctors found. Showing 1 - 6

Dr. Pablo Alberto Casares, M.D Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 4532 N Mesa St Ste 2a, El Paso, TX 79912 Phone: 915-544-0326    Fax: 915-544-2897

Catherine Davenportpollock Wakeham, MD Internal Medicine - Geriatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 329 Vista Del Rey Dr, El Paso, TX 79912 Phone: 915-259-4735

Dr. Jose Luis Aguirre, M.D. Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 6600 N Desert Blvd, El Paso, TX 79912 Phone: 915-790-5700

Radu I Ciubuc, MD Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 125 W Hague Rd Ste 130, El Paso, TX 79902 Phone: 915-217-2163    Fax: 915-217-2166

Dr. Augustine O Bosah, MD Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 6955 N Mesa St Ste 101, El Paso, TX 79912 Phone: 915-351-6600

Ricardo Swatts, NURSE PRACTITIONER Internal Medicine - Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 812 N Virginia St Ste 211b, El Paso, TX 79902 Phone: 915-218-1930    Fax: 915-272-5329

News Archive

Researchers discuss clinical application of bivalirudin in interventional cardiovascular procedures

Anticoagulation is imperative to reduce the incidence of thrombotic complications in patients undergoing percutaneous interventional cardiovascular procedures; however, this is at the expense of increased risk of bleeding.

Study finds severe financial distress among breast cancer survivors

The effects of cancer treatment on a patient's body are easy to see, whether it is a lack of hair on their head, sores on their skin or a look of fatigue on their face.

Erlotinib can reduce lung cancer death by 26% : Study

Three times as many women with advanced lung cancer were alive and had no progression of their cancer 12 months after taking the drug erlotinib (also known as Tarceva) compared to those who did not receive the drug according to new data being presented at the ASCO1 conference today (Monday).

PolyMedix presents data from PMX-30063 defensin-mimetic antibiotic compound Phase 1B study at 8th TSIS

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has presented for the first time to the medical community data from its Phase 1B clinical study with its defensin-mimetic antibiotic compound, PMX-30063.

Read more Medical News

› Verified 1 days ago